Effectiveness and predictors of discontinuation of aripiprazole long acting injection.pdf (300 kB)
Effectiveness and predictors of discontinuation of aripiprazole long-acting injection: a 12-month naturalistic cohort study
journal contribution
posted on 2023-06-09, 23:29 authored by Romaisa Aftab, Marco Pereira, Jed Hewitt, Ray Lyon, Richard WhalePurpose/Background This study aimed to explore the discontinuation rate of aripiprazole long-acting injection (LAI) in a naturalistic clinical setting. Methods/Procedures A retrospective cohort study of 1 year duration was conducted on the first 200 patients registered to receive aripiprazole LAI in Sussex, UK. Rate of discontinuation and the association of robustly recorded clinical variables with discontinuation or a new acute care episode were explored. Findings/Results Of 200 registered, 173 patients initiated aripiprazole LAI and 40% discontinued this by 1 year. Mean discontinuation time was 18 weeks. The commonest discontinuation reason was “patient choice,” independent of efficacy or adverse effects. Not having a diagnosis of schizophrenia spectrum was the only variable significantly associated with treatment continuation after 1 year. No single diagnostic group accounted for this, although a greater continuation rate was observed in those with bipolar disorder. Illness severity factors at baseline, including apparent treatment resistance, had no impact on later aripiprazole LAI discontinuation or on acute service use over the year. Medication-related variables had no identified impact on acute service use. Implications/Conclusions This study supports the clinical utility of aripiprazole LAI for its licensed indications. The 1-year discontinuation rate is equivalent to that in reports of similarly designed studies of paliperidone LAI. Further exploration of nonmedication factors influencing LAI discontinuation is required. Preferential use of aripiprazole LAI over other medications may be supported due to fewer associated metabolic adverse effects.
History
Publication status
- Published
File Version
- Accepted version
Journal
Journal of Clinical PsychopharmacologyISSN
0271-0749Publisher
Lippincott, Williams & WilkinsExternal DOI
Issue
4Volume
41Page range
478-483Department affiliated with
- BSMS Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-04-08First Open Access (FOA) Date
2022-07-02First Compliant Deposit (FCD) Date
2021-04-08Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC